Article: article from journal or magazin.
Nuklearmedizinische Therapie des Phäochromozytoms [Nuclear medical therapy of pheochromocytoma].
Schweizerische Medizinische Wochenschrift
131I-metaiodobenzylguanidine (131I-MIBG) is used for localization procedures in patients with phaeochromocytoma. In high doses and concentrations the same radiopharmaceutical agent can be used for treatment of adrenomedullary tumors. In 4 of our patients, treatment with 131I-MIBG improved the clinical symptoms. In 2 patients with a multilocular phaeochromocytoma, a tumor reduction of some 61% after a total dose of 415 mCi, and of about 10% in the second patient after 365 mCi 131I-MIBG, was measured by computed tomography. In a unilocular intra-adrenal phaeochromocytoma treated with 131I-MIBG, initial clinical improvement was followed by an obstruction of the large abdominal vessels by the growing tumor. There was no close correlation between therapeutic effect and catecholamine secretion. No severe side effects were observed. This new nuclear medical treatment appears to be a reliable therapeutic method for malignant phaeochromocytoma.
3-Iodobenzylguanidine, Adrenal Gland Neoplasms/radionuclide imaging, Adrenal Gland Neoplasms/radiotherapy, Adrenal Medulla, Adult, Aged, Female, Humans, Iodine Radioisotopes/diagnostic use, Iodine Radioisotopes/therapeutic use, Iodobenzenes/diagnostic use, Iodobenzenes/therapeutic use, Male, Middle Aged, Pheochromocytoma/radionuclide imaging, Pheochromocytoma/radiotherapy
Last modification date